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Rising cost of anticancer drugs in Australia
Abstract
Background: Anticancer drugs are often expensive and are contributing to the growing cost of cancer
care. Concerns have been raised about the effect rising costs may have on availability of new anticancer
drugs. Aim: This study aims to determine the recent changes in the costs of anticancer drugs in Australia.
Methods: Publicly available expenditure and prices paid by the Australian Pharmaceutical Benefits
Scheme (PBS) for anticancer drugs from 2000 to 2012 were reviewed. The measures used to determine
changes in cost were total PBS expenditure and average price paid by the PBS per prescription for
anticancer drugs and for all PBS listed drugs. An estimated monthly price paid for newly listed anticancer
drugs was also calculated. Results: Annual PBS expenditure on anticancer drugs rose from A$65 million
in 1999-2000 to A$466 million in 2011-2012; an average increase of 19% per annum. The average price
paid by the PBS per anticancer drug prescription, adjusted for inflation, increased 133% from A$337 to
A$786. The real average annual increase in the price per anticancer drug prescription was more than
double that for all other PBS drugs combined (7.6% vs 2.8%, difference 4.8%, 95% confidence interval
-0.4% to 10.1%, P = 0.07). The median price for a month's treatment of the new anticancer drugs listed
was A$4919 (range A$1003 to A$12578, 2012 prices). Conclusions: PBS expenditure and the price of
anticancer drugs in Australia rose substantially from 2000 to 2012. Dealing with these burgeoning costs
will be a major challenge for our health system and for those affected by cancer. 2014 Royal Australasian
College of Physicians.
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ABSTRACT

Background: Anticancer drugs are often expensive and are contributing to the growing cost of
cancer care. Concerns have been raised about the effect rising costs may have on availability of new
anticancer drugs.
Aims: To determine recent changes in the costs of anticancer drugs in Australia.
Methods: Publically available expenditure and prices paid by the Australian Pharmaceutical Benefits
Scheme (PBS) for anticancer drugs from 2000 to 2012 were reviewed. The measures used to
determine changes in cost were total PBS expenditure and average price paid by the PBS per
prescription for anticancer drugs and for all PBS listed drugs. An estimated monthly price paid for
newly listed anticancer drugs was also calculated.
Results: Annual PBS expenditure on anticancer drugs rose from $65 million in 1999-2000 to $466
million in 2011-2012; an average increase of 19% per annum. The average price paid by the PBS per
anticancer drug prescription, adjusted for inflation, increased 133% from $337 to $786. The real
average annual increase in the price per anticancer drug prescription was more than double that for
all other PBS drugs combined (7.6% v 2.8%, difference 4.8%, 95% confidence interval -0.4% to
10.1%, p=0.07). The median price for a month’s treatment of the new anticancer drugs listed was
$4919 (range $1003 to $12578, 2012 prices).
Conclusions: PBS expenditure and the price of anticancer drugs in Australia rose substantially from
2000 to 2012. Dealing with these burgeoning costs will be a major challenge for our health system
and for those affected by cancer.
Key Words: Drug costs, cancer, health care costs, pharmaceutical benefits scheme, drug access
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Introduction
The cost of health care is rapidly rising. Health spending in Australia in recent years has increased at
a faster rate than spending on all other goods and services.1 This increase in costs creates major
challenges for health care systems, particularly those like Australia’s that are publically funded.
The cost of cancer care has more than doubled over the past 20 years with a most recent estimate of
over $5 billion per year in 2009.2 The causes are complex and include the growing availability and
use of new and expensive anticancer drugs.3 Spending on drugs is one of the fastest growing
components of health care costs in developed countries.1 Anticancer drugs are estimated to
represent 10% of cancer costs in OECD countries. 4
Concerns have been raised about the effects of rising prices on the availability of new anticancer
drugs.4, 5, 6 In Australia, widespread access to expensive drugs depends on whether they are listed on
the Pharmaceutical Benefits Scheme (PBS). PBS listing requires a favourable assessment of costeffectiveness which is not forthcoming for every effective anticancer drug. Gaining access to
effective anticancer drugs that are not listed on the PBS is a major dilemma for patients and doctors.
However, we were unable to find published reports focusing on the costs of anticancer drugs in
Australia that might inform clinicians and patients facing this increasingly common challenge.
The aims of this study were to 1) determine changes in PBS expenditure on anticancer drugs from
2000 to 2012; 2) compare price increases for anticancer drugs to other drugs listed on the PBS; 3)
determine the monthly price paid for newly listed anticancer drugs; and, 4) consider the reasons for,
and implications of, our findings.
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Methods
PBS expenditure and average prescription prices
We determined annual expenditure and prescription volumes for all PBS listed drugs, and for
anticancer drugs (using the PBS subcategory Anti-neoplastics), from the publicly available
Pharmaceutical Benefits Pricing Authority Annual Reports (2000- 2010) and Pharmaceutical Benefits
Scheme Expenditure and Prescription reports (2003-2012).7, 8 The average price paid by the PBS per
prescription was calculated by dividing the total expenditure by prescription volumes for each year.
Patient co-payments were not included in these calculations. All prices were adjusted to reflect
2012 values (“real” prices) using the average health prices inflation figure of 3.0% from 1999-2000 to
2010-2011.1, 9
Monthly prices of newly listed anticancer drugs
PBS schedules from January 2000 to June 2012 were searched for listings of new anticancer drugs
that were categorised under the PBS subcategory Anti-neoplastics.10 Drugs that were listed on the
PBS prior to 2000 but granted additional indications from 2000 to 2012 were not included. Prices
paid by the PBS for a month’s treatment (28 days) were calculated for each new anticancer drug
using the recommended schedule and ‘typical’ dose calculated for a patient with body surface area
(1.73m2) and/or body weight (70kg).11 If a drug dose varied during a treatment protocol then the
dose used for the majority of the protocol was chosen for the typical dose calculation.
For each new anticancer drug listed, the dispensed price for maximum quantity was determined
from the PBS schedule in the year the drug was listed.10 An approximation of the price paid by the
PBS for each dose was determined by calculating the proportion of the maximum quantity required
for a typical dose. For intravenous drugs, we determined the price using the most efficient
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combination of vials required for the typical dose. The estimated price paid per month was
determined by multiplying the price per dose by the number of doses required per month.
We did not consider anticancer drugs listed under subcategories other than Anti-neoplastics, for
example, endocrine therapies, vaccines, supportive care drugs, and drugs for non-melanoma skin
cancer.
Statistical analysis
Descriptive statistics were used to analyse the monthly prices of new drugs listed on the PBS. A
paired t-test was used to compare the annual average price rise in anticancer drugs to the annual
average price rise for all other PBS listed drugs combined. Data was analysed with SPSS version 20.
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Results
PBS expenditure on anticancer drugs and the average price paid by the PBS for anticancer drugs
both climbed markedly from 2000 to 2012. Expenditure on anticancer drugs rose from $64.8 million
in 1999-2000 to $466.3 million in 2011-2012. The peak expenditure occurred in 2010-2011 and was
$561.3 million (Figure 1). PBS expenditure, excluding anticancer drugs, climbed at a lower rate from
$3.1 billion in 1999-2000 to $8.6 billion in 2011-2012. The average annual increase in PBS
expenditure on anticancer drugs over this time period was 19.1% compared with 9.0% for all other
drugs combined. Expenditure on anticancer drugs was a small but growing proportion of total PBS
expenditure: 2.0% in 1999-2000, 6.4% in 2010-2011 and 5.1% in 2011-2012 (Figure 2).
The average price paid by the PBS per anticancer drug prescription increased 133% in real terms
from $338 in 1999-2000 to $786 in 2011-2012 (all adjusted to 2012 prices, Figure 3). The average
price reached a peak of $850 in 2009-2010. The average price paid by the PBS for all prescriptions,
excluding anticancer drugs, increased 37% in real terms from $32 to $44. The real average annual
increase in the average price paid by the PBS per anticancer drug prescription from 2000 to 2012
was more than double that for all other PBS drugs combined (7.6% v 2.8%) but this trend was not
statistically significant (difference 4.8%, 95% confidence interval -0.4% to 10.1%, p=0.07).
There were 23 new anticancer drugs listed on the PBS between January 2000 and June 2012 (Table
1). Most drugs were listed in the second half of the study period and 14 of the 23 (61%) were listed
for treatment of solid malignancies. Chronic myeloid leukaemia was the malignancy with the highest
number of new drugs listed. The median price for a month’s treatment of the new anticancer drugs
listed during the study period was $4919 (2012 prices). Prices per month for individual drugs ranged
from $1003 to $12578 (Figure 4; See Appendix 1 for list of individual drugs).
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Discussion
This is the first report in the medical literature describing the increasing costs of anticancer drugs to
the Australian PBS. The 7-fold increase in expenditure from 2000 to 2012 is identical to that seen in
Europe from 1993 to 2004.12 The median price paid by the PBS for a year’s treatment of the new
anticancer drugs listed during the study period was approximately $60,000 in 2012 prices. The
average price paid by the PBS per prescription for anticancer drugs has more than doubled in real
terms, climbing an average of 7.6% per annum, which echo US price rises over a similar period. 13 In
comparison, the average price paid by the PBS for all other PBS drugs combined has increased more
gradually.
The many and complex reasons for the rise in PBS expenditure on anticancer drugs include
increases in the prevalence of cancer and in the proportions of patients for whom there are suitable
treatments.14 The 7.6% rise per annum in the average price paid by the PBS per prescription for
anticancer drugs is driven by rapid growth in the number of new expensive drugs. This may explain
why the average prices paid for prescriptions used to treat other high burden diseases, in which the
number of newly available drugs has grown more slowly, have changed much less. For example for
drugs used to treat diabetes, the average annual increase in the average prescription price paid by
the PBS over the study period was 1.6%, while for lipid-modifying drugs and psychoanaleptics used
to treat mental illness, there have been average annual falls of 2.4% and 2.0% respectively.7, 8
The effort to develop newer and better drugs to treat patients with cancer has resulted in over 70
anticancer drugs being currently listed on the PBS, many with multiple indications. 10 The US Food
and Drug Administration approved 12 new anticancer drugs in 2012 alone.15 Some have argued that
the price of new anticancer drugs is increasing rapidly because of the increasing cost of drug
development , with estimates ranging from $500 million to $2 billion per new drug approved.16 This
figure includes substantial expenditure on drugs that fail to reach the market. For example, it is
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estimated that of the 920 drugs tested in clinical trials between 1990 and 2006, only 32 were
approved in the US.17 Debate continues about whether these costs justify the asking price for new
anticancer drugs, particularly when marketing budgets and profits are also substantial. 15
Many new anticancer drugs are molecularly-targeted and are substantially more expensive than
traditional cytotoxic drugs.12 The beneficial effects of targeted anticancer drugs are usually confined
to a subgroup of all patients. The presence of a testable molecular target offers the potential to
identify and treat only those for whom treatment is most likely to be beneficial. This reduces the
total number of patients to be treated, which should reduce total costs, but also provides a
commercial rationale for increasing the price to make up for a smaller market. Another factor
tending to increase the total costs of molecularly targeted agents is that they are often used for
longer periods than their cytotoxic counterparts. 18 Furthermore, older anticancer drugs are
commonly not phased out with the introduction of new drugs but rather used sequentially or in
combination which also significantly contributes to growing costs. 19
Reductions in prices of anticancer drugs due to the availability of generic equivalents can help
mitigate the effect of expensive new drugs on the growth rate of expenditure. Australia’s pricing
and reimbursement system may result in a lower price for new drugs, but a higher price for generic
drugs, in comparison with similarly developed countries. 20 Therefore, the potential cost savings due
to the use of generic drugs may not be as substantial in Australia as in other developed countries, an
effect which is compounded by the speed of oncology drug development. Newer, more expensive
versions of existing anticancer drugs that are either equivalent or offer only modest additional
benefits may penetrate the market and reduce the use of cheaper generics by making them seem
suboptimal and superseded.19
This study is limited by its short time frame (2000 to 2012) and focus on drugs listed under the Antineoplastics sub-category which does not include endocrine drugs used to treat breast cancer or
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prostate cancer or immunomodulating drugs such as the colony stimulating factors commonly used
in conjunction with chemotherapy. Our estimates of the monthly prices for new anticancer drugs are
based on the price listed on the PBS schedule, whereas the actual prices paid by the PBS are
negotiated in confidence by the Pharmaceutical Benefits Pricing Authority, and can involve special
pricing arrangements and risk sharing agreements.21 This study also ignores variations in total costs
attributable to variations in durations of use.
It was surprising to see that total expenditure on anticancer drugs and the average prescription
price paid by the PBS dropped in 2011-2012. This was partly due to PBS listing of cheaper generics
for high use drugs such as docetaxel and the introduction of the Australian Commonwealth
government’s Efficient funding of chemotherapy drugs policy.22
Despite rapid rises in total expenditure on anticancer drugs, and in the average price paid by the PBS
per prescription, anticancer drugs accounted for less than 6% of the total PBS budget in 2012.
Anticancer drugs are estimated to account for about 10-15% of expenditure on cancer care;
hospitalisation of cancer patients is estimated to account for about 70%.23 Nevertheless, the rising
costs of anticancer drugs substantially strains publicly funded health care systems like Australia’s.
The Pharmaceutical Benefits Advisory Committee (PBAC), the body that makes recommendations to
the Federal health minister as to whether new drugs should be publically reimbursed, is just as likely
to make a positive recommendation for an anticancer drug as it is for other drugs.24 Despite this, the
high price asked for many new anticancer drugs often results in an initial rejection for PBS listing due
to the PBAC’s reasonable assessment of unsatisfactory cost-effectiveness. This delays, and therefore
reduces access to reimbursed new anticancer drugs.
This study indicates that patients wanting to use new anticancer drugs that are not reimbursed
currently face bills of about $5000 per month. Physicians will increasingly find themselves in the
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difficult position of having to discuss with patients whether the financial toxicity of these new drugs
is warranted by their benefits, which are often relatively modest. 25
This study demonstrates a substantial increase in the average prescription price paid by the PBS for
anticancer drugs, over and above inflation for health prices in general, alongside a rapid growth in
total government expenditure on anticancer drugs. Dealing with these burgeoning costs at both the
societal level, and for individuals, while retaining effective, equitable and readily accessible cancer
care, poses a major challenge for all health systems.
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Table 1: Characteristics of newly listed anticancer drugs (2000 – 2012).
Drug characteristics

N (%)

Total

23

Year PBS listed

2000 – 2006

9 (39)

2007 – 2012

14 (61)

Drug class

Cytotoxics

8 (35)

Tyrosine kinase inhibitors

8 (35)

Monoclonal antibodies

3 (13)

Other

4 (17)

Tumour type

Chronic myeloid leukaemia

4 (17)

Myeloma

3 (13)

Breast

3 (13)

Colorectal

3 (13)

Lung

3 (13)

Other

7 (30)
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Figure 1: PBS expenditure on anticancer drugs (without adjustment for inflation)

Figure 2: Percentage of PBS expenditure on anticancer drugs
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Figure 3: Average price paid by the PBS per prescription: all anticancer drugs vs. all other PBS
drugs (adjusted to 2012 prices)

Figure 4: Monthly prices for newly listed anticancer drugs (adjusted to 2012 prices)
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Appendix 1: Monthly prices for newly listed anticancer drugs (adjusted to 2012 prices)
Drug name

Year PBS listed

Tumour type

Monthly
price ($)

Temozolomide

2000

Glioblastoma multiforme

4830

Irinotecan

2000

Colorectal cancer

3946

Imatinib

2001

Chronic myeloid leukaemia

8461

Oxaliplatin

2002

Colorectal cancer

3448

Gefitinib

2004

Non-small cell lung cancer

4920

Fotemustine

2005

Melanoma

1696

Pemetrexed

2005

Non-small cell lung cancer

6052

Thalidomide

2006

Myeloma

1003

Trastuzumab

2006

Breast cancer

4777

Dasatinib

2007

Chronic myeloid leukaemia

5483

Cetuximab

2007

Head and neck cancer

8424

Bortezomib

2007

Myeloma

10462

Lapatinib

2008

Breast cancer

3778

Fludarabine

2008

Chronic lymphocytic

1118

leukaemia
Erlotinib

2008

Non-small cell lung cancer

3375

Nilotinib

2008

Chronic myeloid leukaemia

5999

Sorafenib

2009

Hepatocellular carcinoma

6585

nab-Paclitaxel

2009

Breast cancer

3319

Sunitinib

2009

Renal cell carcinoma

5024

Bevacizumab

2009

Colorectal cancer

3960

Arsenic trioxide

2009

Acute promyelocytic

12578

leukaemia
Lenalidomide

2009

Myeloma

7356

Azacitidine

2011

Myelodysplatic syndrome,

5145

acute myeloid leukaemia,
chronic myeloid leukaemia

